SG11202100983XA - Method of producing tetracyclic compound - Google Patents
Method of producing tetracyclic compoundInfo
- Publication number
- SG11202100983XA SG11202100983XA SG11202100983XA SG11202100983XA SG11202100983XA SG 11202100983X A SG11202100983X A SG 11202100983XA SG 11202100983X A SG11202100983X A SG 11202100983XA SG 11202100983X A SG11202100983X A SG 11202100983XA SG 11202100983X A SG11202100983X A SG 11202100983XA
- Authority
- SG
- Singapore
- Prior art keywords
- tetracyclic compound
- producing
- producing tetracyclic
- compound
- tetracyclic
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B61/00—Other general methods
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018165313 | 2018-09-04 | ||
| PCT/JP2019/034543 WO2020050241A1 (en) | 2018-09-04 | 2019-09-03 | Method of producing tetracyclic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100983XA true SG11202100983XA (en) | 2021-03-30 |
Family
ID=69722303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100983XA SG11202100983XA (en) | 2018-09-04 | 2019-09-03 | Method of producing tetracyclic compound |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11939322B2 (en) |
| EP (1) | EP3848361B1 (en) |
| JP (1) | JP7167171B2 (en) |
| KR (1) | KR102635225B1 (en) |
| CN (1) | CN112585126B (en) |
| AR (1) | AR116113A1 (en) |
| AU (1) | AU2019337018B2 (en) |
| BR (1) | BR112021001145A2 (en) |
| CA (1) | CA3107270A1 (en) |
| ES (1) | ES3010145T3 (en) |
| HR (1) | HRP20250284T1 (en) |
| HU (1) | HUE070227T2 (en) |
| IL (1) | IL281079B2 (en) |
| MX (1) | MX2021002311A (en) |
| PL (1) | PL3848361T3 (en) |
| SG (1) | SG11202100983XA (en) |
| TW (1) | TWI825163B (en) |
| WO (1) | WO2020050241A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240115578A1 (en) | 2021-01-29 | 2024-04-11 | Chugai Seiyaku Kabushiki Kaisha | Drug composition for treating pediatric cancers |
| CN117024410A (en) * | 2023-08-15 | 2023-11-10 | 上海药坦药物研究开发有限公司 | Airotinib intermediate and preparation method thereof |
| WO2025067412A1 (en) * | 2023-09-28 | 2025-04-03 | 重庆博腾制药科技股份有限公司 | Preparation method for anti-tumor drug intermediate |
| CN120081779A (en) * | 2025-02-19 | 2025-06-03 | 江苏天士力帝益药业有限公司 | Alectinib impurity 01A and control method thereof |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS506987B1 (en) | 1970-02-17 | 1975-03-19 | ||
| JPS4918630B1 (en) | 1970-07-29 | 1974-05-11 | ||
| JPS5859712U (en) | 1981-10-16 | 1983-04-22 | ニチバン株式会社 | label pasting machine |
| JPH0892090A (en) | 1994-07-26 | 1996-04-09 | Tanabe Seiyaku Co Ltd | Pharmaceutical composition |
| DK0695755T3 (en) | 1994-08-04 | 1999-06-28 | Hoffmann La Roche | pyrrolocarbazoles |
| IL126762A0 (en) | 1996-05-01 | 1999-08-17 | Lilly Co Eli | Halo-substituted protein kinase c inhibitors |
| HUP0104657A3 (en) | 1998-12-24 | 2002-07-29 | Astellas Pharma Inc Chuo Ku | Imidazole compounds and pharmaceutical compositions containing them |
| CA2372032A1 (en) | 1999-05-14 | 2000-11-23 | Rodney W. Rickards | Compounds and therapeutic methods |
| GB0030417D0 (en) | 2000-12-13 | 2001-01-24 | Pharma Mar Sa | An anticancer lead compound isolated from a New Zealand ascidian |
| FR2841138B1 (en) | 2002-06-25 | 2005-02-25 | Cll Pharma | SOLID PHARMACEUTICAL COMPOSITION COMPRISING A LIPOPHILIC ACTIVE INGREDIENT, ITS PREPARATION PROCESS |
| JP2007501857A (en) | 2003-02-28 | 2007-02-01 | イノテック ファーマシューティカルズ コーポレーション | Tetracyclic benzamide derivatives and methods of use thereof |
| EP1454992B1 (en) | 2003-03-07 | 2006-05-31 | Istituto Nazionale Per Lo Studio E La Cura Dei Tumori | Anaplastic lymphoma kinase assay, reagents and compositions thereof |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| JP4836788B2 (en) | 2003-07-23 | 2011-12-14 | エグゼリクシス， インコーポレイテッド | Undifferentiated lymphoma kinase modulators and methods of use thereof |
| US7378414B2 (en) | 2003-08-25 | 2008-05-27 | Abbott Laboratories | Anti-infective agents |
| DE602004014969D1 (en) | 2003-11-21 | 2008-08-21 | Novartis Ag | 1H-IMIDAZOCHINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS |
| CA2548600A1 (en) | 2003-12-12 | 2005-06-23 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
| US20090155903A1 (en) | 2004-03-19 | 2009-06-18 | Myriad Genetics, Incorporated | Pharmaceutical composition and method |
| JP4927704B2 (en) | 2004-03-19 | 2012-05-09 | シュペーデル・エクスペリメンタ・アーゲー | Organic compounds |
| EP1730128A1 (en) | 2004-03-31 | 2006-12-13 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| KR20070038496A (en) | 2004-06-02 | 2007-04-10 | 파마시클릭스,인코포레이티드 | BA factor inhibitor |
| BR122020017756B1 (en) | 2004-08-26 | 2022-02-15 | Pfizer Inc | Use of enantiomerically pure aminoetheroaryl compounds in the preparation of a drug for the treatment of abnormal cell growth in a mammal |
| US7091202B2 (en) | 2004-09-15 | 2006-08-15 | Bristol-Myers Squibb Company | 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators |
| GB0517329D0 (en) | 2005-08-25 | 2005-10-05 | Merck Sharp & Dohme | Stimulation of neurogenesis |
| CA2626446A1 (en) | 2005-11-07 | 2007-05-18 | Irm Llc | Compounds and compositions as ppar modulators |
| US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
| CN101535276B (en) | 2006-10-23 | 2013-08-28 | 赛福伦公司 | 2,4-Diaminopyrimidine-fused bicyclic derivatives as ALK and c-MET inhibitors |
| US8546394B2 (en) | 2007-04-17 | 2013-10-01 | Bristol-Myers Squibb Company | Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors |
| TWI389893B (en) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | Di (arylamino) ary1 compound |
| PH12013501594A1 (en) | 2007-07-20 | 2014-05-12 | Nerviano Medical Sciences Srl | Substituted indazole derivatives active as kinase inhibitors |
| JP5583592B2 (en) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | IDO inhibitor |
| ES2510866T3 (en) | 2008-03-13 | 2014-10-21 | Daiichi Sankyo Company, Limited | Improvement of the solubility of a preparation containing olmesartan medoxomil |
| CN102574830A (en) | 2009-05-07 | 2012-07-11 | 阿斯利康(瑞典)有限公司 | Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750 |
| GB0910046D0 (en) | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
| EP3613729A1 (en) | 2009-06-10 | 2020-02-26 | Chugai Seiyaku Kabushiki Kaisha | Tetracyclic compounds |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| CA2808210C (en) | 2010-08-20 | 2019-10-01 | Chugai Seiyaku Kabushiki Kaisha | Tetracyclic compounds having alk inhibitory activity and compositions thereof |
| JP5006987B2 (en) | 2010-11-22 | 2012-08-22 | 中外製薬株式会社 | Medicine containing tetracyclic compound |
| SI2902029T1 (en) | 2012-09-25 | 2018-11-30 | Chugai Seiyaku Kabushiki Kaisha | Ret inhibitor |
| WO2015163447A1 (en) | 2014-04-25 | 2015-10-29 | 中外製薬株式会社 | Novel crystal of tetracyclic compound |
| WO2015163448A1 (en) | 2014-04-25 | 2015-10-29 | 中外製薬株式会社 | Preparation containing tetracyclic compound at high dose |
| EP3157569B1 (en) | 2014-06-18 | 2019-07-24 | F.Hoffmann-La Roche Ag | New pharmaceutical composition comprising non-ionic surfactants |
| TWI831347B (en) | 2014-08-08 | 2024-02-01 | 日商中外製藥股份有限公司 | Solid dispersion containing amorphous body of tetracyclic compound and preparation |
| CN104402862B (en) * | 2014-11-12 | 2016-10-05 | 苏州明锐医药科技有限公司 | Ai Li is for the preparation method of Buddhist nun |
| US9573932B2 (en) * | 2015-03-02 | 2017-02-21 | Yong Xu | Synthesis of intermediates in the preparation of ALK inhibitor |
| WO2017073706A1 (en) * | 2015-10-30 | 2017-05-04 | 中外製薬株式会社 | DIHYDRONAPHTHO[2,3-b]BENZOFURAN DERIVATIVE |
| CN106928184B (en) | 2017-04-21 | 2019-09-20 | 湖南博奥德药业有限公司 | A kind of Ai Le replaces the preparation method of Buddhist nun |
| CN106928185B (en) | 2017-04-21 | 2019-09-20 | 湖南博奥德药业有限公司 | A kind of Ai Le replaces the preparation method of Buddhist nun |
| CN107033124B (en) * | 2017-04-21 | 2019-09-20 | 湖南博奥德药业有限公司 | A kind of Ai Le replaces the preparation method of Buddhist nun |
-
2019
- 2019-09-03 BR BR112021001145-5A patent/BR112021001145A2/en unknown
- 2019-09-03 WO PCT/JP2019/034543 patent/WO2020050241A1/en not_active Ceased
- 2019-09-03 HU HUE19856540A patent/HUE070227T2/en unknown
- 2019-09-03 EP EP19856540.0A patent/EP3848361B1/en active Active
- 2019-09-03 MX MX2021002311A patent/MX2021002311A/en unknown
- 2019-09-03 CA CA3107270A patent/CA3107270A1/en active Pending
- 2019-09-03 SG SG11202100983XA patent/SG11202100983XA/en unknown
- 2019-09-03 PL PL19856540.0T patent/PL3848361T3/en unknown
- 2019-09-03 ES ES19856540T patent/ES3010145T3/en active Active
- 2019-09-03 CN CN201980056366.1A patent/CN112585126B/en active Active
- 2019-09-03 HR HRP20250284TT patent/HRP20250284T1/en unknown
- 2019-09-03 TW TW108131697A patent/TWI825163B/en active
- 2019-09-03 AR ARP190102518A patent/AR116113A1/en unknown
- 2019-09-03 US US17/271,437 patent/US11939322B2/en active Active
- 2019-09-03 JP JP2020541220A patent/JP7167171B2/en active Active
- 2019-09-03 AU AU2019337018A patent/AU2019337018B2/en active Active
- 2019-09-03 IL IL281079A patent/IL281079B2/en unknown
- 2019-09-03 KR KR1020217005965A patent/KR102635225B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019337018A1 (en) | 2021-03-18 |
| IL281079B2 (en) | 2024-12-01 |
| EP3848361B1 (en) | 2025-01-22 |
| JPWO2020050241A1 (en) | 2021-08-30 |
| IL281079B1 (en) | 2024-08-01 |
| CA3107270A1 (en) | 2020-03-12 |
| IL281079A (en) | 2021-04-29 |
| MX2021002311A (en) | 2021-04-28 |
| EP3848361C0 (en) | 2025-01-22 |
| WO2020050241A1 (en) | 2020-03-12 |
| ES3010145T3 (en) | 2025-04-01 |
| EP3848361A4 (en) | 2022-06-15 |
| PL3848361T3 (en) | 2025-07-07 |
| BR112021001145A2 (en) | 2021-04-20 |
| US20220372025A1 (en) | 2022-11-24 |
| CN112585126B (en) | 2024-05-07 |
| AR116113A1 (en) | 2021-03-31 |
| US11939322B2 (en) | 2024-03-26 |
| JP7167171B2 (en) | 2022-11-08 |
| AU2019337018B2 (en) | 2024-03-07 |
| HRP20250284T1 (en) | 2025-04-25 |
| CN112585126A (en) | 2021-03-30 |
| KR102635225B1 (en) | 2024-02-07 |
| HUE070227T2 (en) | 2025-05-28 |
| TWI825163B (en) | 2023-12-11 |
| TW202024050A (en) | 2020-07-01 |
| EP3848361A1 (en) | 2021-07-14 |
| KR20210053890A (en) | 2021-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268470A (en) | Method for producing multispecific antibodies | |
| SG11202005448UA (en) | Manufacturing method of mounting structure | |
| IL281079A (en) | Method of producing a tetracyclic compound | |
| GB201806072D0 (en) | Methods of manufacture | |
| SG11202103664WA (en) | Process for producing perfluoroalkyne compound | |
| SG11201911164WA (en) | Method for preparing intermediate of 4-methoxypyrrole derivative | |
| GB201804594D0 (en) | Bonegraft substituteand method of manufacture | |
| HUE065555T2 (en) | Method for producing butadiene compound | |
| GB201704089D0 (en) | Method of manufacture | |
| GB201802839D0 (en) | Method of manufacture | |
| SG11201907182QA (en) | Method for producing perfluoroalkadiene compounds | |
| PT3864118T (en) | Method of producing biodiesel | |
| IL281431A (en) | Methods of producing pyrazole compounds | |
| GB201805904D0 (en) | Methods of Manufacture | |
| SG11202111060VA (en) | Method for producing perfluoroalkyne compound | |
| IL275434B (en) | Method for producing thiocarboxamidine salt compound | |
| HUE066667T2 (en) | Method for producing bonded structure | |
| PL3733651T3 (en) | Method for producing calcobutrol | |
| EP3257834A4 (en) | Method of producing c2-c4 carbonyl compounds | |
| ZA201808254B (en) | Method for producing crystal of uracil compound | |
| IL287063A (en) | Method for producing biotissue-like structure | |
| SG11202103673UA (en) | Method for producing perfluorocycloalkene compound | |
| PL4054356T3 (en) | Method of producing an aerosol-generating element | |
| SG11202101704VA (en) | Method of producing piperylene | |
| SG11202106891PA (en) | Method for producing cyclobutene |